Drugs / KN060
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07191899 | Aug 2025 → Dec 2026 expected | hypertensive disorder | Suzhou Alphamab Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07201467 | Aug 2025 → Aug 2027 expected | end stage renal failure | Suzhou Alphamab Co., Ltd. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06180889 | Dec 2023 → Dec 2025 overdue | osteoarthritis, knee | Suzhou Alphamab Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KN060 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06180889 ↗ |
| Route | Intravenous | “Single dose of KN060 administered as intravenous infusion” NCT06180889 ↗ |